Galectin Therapeutics Q3 loss narrows

Galectin Therapeutics

14/11/2025 13:07

Overview

Galectin Therapeutics Q3 net loss narrows to $8.2 mln from $11.2 mln last year

Operating expenses for Q3 decrease due to NAVIGATE trial conclusion

Company has $11.5 mln cash and $10 mln credit line to fund operations through June 2026

Outlook

Galectin expects FDA feedback on NAVIGATE data by year-end

Company focuses on advancing FDA dialogue for belapectin

Galectin exploring strategic opportunities for belapectin program

Result Drivers

Research and development expenses for the quarter ended September 30, 2025 were $2.6 million compared with $7.6 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.13
Q3 Net Income
-$8.18 mln
Q3 Operating Expenses
$4.20 mln
Q3 Operating Income
-$4.20 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Galectin Therapeutics Inc is $6.00, about 7.8% above its November 13 closing price of $5.53

Press Release: ID:nGNX6xfZlS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)